Evercore ISI initiated coverage of Revolution Medicines (RVMD) with an Outperform rating and $140 price target With the anticipated launch of daraxonrasib, Revolution Medicines is “poised for a potential breakthrough in oncology,” the analyst tells investors. With strategic distractions fading, the firm sees “a promising entry point” ahead of key Phase 3 data in pancreatic cancer expected in the first half of 2026, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Is RVMD a Buy, Before Earnings?
- Revolution Medicines placed on ‘Positive Catalyst Watch’ at JPMorgan
- Revolution Medicines put volume heavy and directionally bearish
- Revolution Medicines price target raised to $122 from $92 at JPMorgan
- Revolution Medicines doses first patient in trial evaluating RMC-5127